EDAP TMS S.A. ADR | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
32,030.70
35,392.40
35,596.30
39,392.80
40,319.10
46,226.10
Cost of Goods Sold (COGS) incl. D&A
19,634.80
20,591.90
20,382.40
21,239.00
23,616.70
26,268.30
Gross Income
12,395.90
14,800.40
15,214.00
18,153.80
16,702.50
19,957.80
SG&A Expense
17,545.10
18,147.40
15,358.50
17,721.30
18,988.80
22,317.30
EBIT
4,410.90
2,978.30
44.20
-
2,286.30
2,359.50
Unusual Expense
1,339.50
2,275.40
2,259.20
4,408.20
3,010.50
1,048.80
Non Operating Income/Expense
1,636.10
459.80
771.50
115.00
1,025.30
634.70
Interest Expense
2,616.50
85.90
70.60
63.10
49.60
131
Pretax Income
7,245.50
1,207.70
1,495.50
4,915.90
330.50
784.50
Income Tax
566.70
531.20
344.30
665.90
437.60
385.80
Consolidated Net Income
6,678.80
676.50
1,839.80
4,250.00
768.10
398.80
Net Income
6,678.80
676.50
1,839.80
4,250.00
768.10
398.80
Net Income After Extraordinaries
6,678.80
676.50
1,839.80
4,250.00
768.10
398.80
Net Income Available to Common
6,678.80
676.50
1,839.80
4,250.00
768.10
398.80
EPS (Basic)
0.32
0.03
0.08
0.15
0.02
0.01
Basic Shares Outstanding
20,593.70
23,600.40
25,022.00
27,823.30
28,961.90
28,997.90
EPS (Diluted)
0.32
0.03
-
0.14
0.03
0.01
Diluted Shares Outstanding
20,593.70
23,600.40
25,022.00
29,365.60
28,961.90
28,997.90
EBITDA
2,842.60
1,789.10
1,150.00
1,566.40
512.10
617
Other Operating Expense
738.30
368.70
188.70
-
-
-
Non-Operating Interest Income
78.50
41.00
18.80
23.20
20.30
22.40

About EDAP TMS

View Profile
Address
Parc d'Activités la Poudrette-Lamart
Vaulx-en-Velin Rhone-Alpes 69120
France
Employees -
Website http://www.edap-tms.com
Updated 07/08/2019
EDAP TMS SA develops, produces and markets minimally invasive medical devices for urological diseases. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment, Ablatherm-HIFU is approved and commercialized in Europe as a treatment for prostate cancer and is currently under regulatory review in the U.